Ron Bentsur is a seasoned executive in the biotechnology sector and currently serves as the Chairman, President, and CEO of Nuvectis Pharma, a precision oncology company he co-founded in 2020. With a track record of leading successful biotech ventures, Ron brings over two decades of experience in drug development, regulatory strategy, and commercial execution.

Prior to founding Nuvectis, Ron held several prominent leadership positions:

• CEO of UroGen Pharma(2015–2019)
• CEO of Keryx Biopharmaceuticals(2009–2015)
• CEO of XTL Biopharmaceuticals(2006–2009)
• CFO of Keryx Biopharmaceuticals(2000–2006)
• Board Director at Stemline Therapeutics until its acquisition by Menarini in 2020

Track Record of Success:

Ron successfully led the clinical development and U.S. commercial launches of Jelmyto (UroGen) and Auryxia (Keryx), two first-in-class therapies. Under his leadership, both companies secured key regulatory approvals, built robust commercial infrastructures, and executed strategic partnerships—including a global collaboration at UroGen and an ex-U.S. development deal for Auryxia.

Ron’s proven ability to advance innovative therapies from development to market has made him a recognized leader in the biotech industry.